Biofuture 2022 第四届生物医药未来领袖峰会(深圳站) – 活动发布 – 活动Q – 轻松发布会议展览培训活动  

Biofuture 2022 第四届生物医药未来领袖峰会(深圳站)

Biofuture 2022 第四届生物医药未来领袖峰会
时间:2022年6月27-28日
地点:深圳
三大主题论坛齐聚:第四届下一代抗体药技术创新论坛,第四届细胞与基因治疗创新论坛,第三届CDMO未来发展论坛
近日国家发展改革委、商务部联合发布《关于深圳建设中国特色社会主义先行示范区放宽市场准入若干特别措施的意见》,其中包含六大领域、24条特别措施,支持深圳大胆闯、大胆试。意见提出创新医药健康领域市场准入机制。支持干细胞治疗、免疫治疗、基因治疗、新型抗体药,疫苗等新型医疗产品、技术研发。
我们诚邀您三月相聚鹏城,共襄盛会!
会议规模:1500人+专业观众,100+的行业大咖,50+优秀厂商领先技术展示,超过50%的听众来自医药/CRO/CDMO/Biotech企业
支持单位:广东医谷,美柏医健,深圳市生物医药促进会,深圳市生命科技产学研资联盟,深圳市细胞治疗技术协会,深圳市生命科学与生物技术协会,深圳市生命科学行业协会,东莞市医药行业协会,深圳市罗湖区科技创新局
 
第四届创新抗体药物发现论坛主要话题:
ADCs全球与国内趋势纵览/Overview of ADCs Global and Domestic Trends
ADC药物定点偶联技术及成药性的研究趋势纵览/ Overview of the research
ADC药物研发面临的挑战和机遇/Challenges and opportunities facing ADC干细胞药物的发现研究
下一代ADC药物研发/Next-generation ADC drug development
抗体偶联药物(ADC)的临床方案设计与检测/ Design and testing of the clinical program of antibody-conjugated drugs (ADC)
ADC药物蓬勃发展: CDMO发展机遇和挑战/ ADC drugs are booming: CDMO development opportunities and challenges
迎接挑战与机遇,抗体药物研发战略布局/Facing challenges and opportunities, the strategic layout of antibody drug R&D
CD28是否会打破双特异抗体的格局/Will CD28 break the pattern of bispecific antibodies?
双特异性抗体创新药研发: 新靶点和组合/Bispecific antibody innovation drug development: new targets and combinations
新一代免疫检查点药物开发/Development of a new generation of immune checkpoint drugs
圆桌讨论: 百花齐放的双抗/The booming of Bispecific antibody drug development
重组蛋白类药物的研发现状与趋势/Current status and trend of research and development of recombinant protein drugs
靶向CD47/SIRPα药物研发进展和未来展望/Development and future prospects of drugs targeting CD47/SIRPα
以VEGF(R)为靶点药物的研发进展/Development progress of VEGF(R) target drugs
靶点ROR1会是下一个PD-1?/Will the target ROR1 be the next PD-1?
靶向NK细胞治疗肿瘤的双特异性抗体药物开发/Development of bispecific antibody drugs targeting NK cells to treat tumors
Claudin 18.2下一代创新免疫疗法黑马/Claudin 18.2 The next generation of innovative immunotherapy dark horse
AI赋能新形多肽药物研发/AI empowers R&D of new peptide drugs
多肽偶联药物(PDC) ——继ADC之后,新一代肿瘤靶向药物已然来临/Polypeptide-conjugated drugs (PDC)-after ADC, a new generation of tumor-targeted drugs has arrived
重组蛋白类药物的研发现状与趋势/Current status and trend of research and development of recombinant protein drugs
第四届细胞与基因治疗创新论坛:
细胞免疫治疗产业发展趋势与政策环境解读/Development Trends and Policies of Cellular Immunotherapy Industry
CART产品开发新靶点新思路/CART product development new targets and new ideas
CART免疫细胞治疗的工艺开发,验证和产业化/Process development, verification and industrialization of CART immune cell therapy
双靶点CAR-T细胞治疗癌症的研究进展和展望/Research progress and prospects of dual-target CAR-T cell therapy for cancer
小组讨论: CAR-T细胞治疗火热的当下面临的潜在问题,未来破局之道 The potential problems faced by CAR-T cell therapy at the moment, and the future outlook
异体γδT细胞治疗新突破
广谱多功能CAR-NK 细胞药物的研发/Development of Multifunctional Integrated CAR-NK Cell Drug
基因治疗药物研发与分析/Gene therapy drug development and analysis
溶瘤病毒产品的研发进展/Research and development progress of oncolytic virus products
下一代腺病毒载体+ 新技术助基因治疗腾飞/Next-generation Adenovirus Vector + New Technology Helps Gene Therapy Take Off
基因编辑技术及其应用/Gene editing technology and its application
从小众到大众→通用CAR-T未来已来/From niche to mass → General CAR-T’s future is here
肿瘤微环境下的下一代细胞治疗产品开发/Development of next-generation cell therapy products in the tumor microenvironment
病毒载体开发和工艺优化/Viral vector development and process optimization
溶瘤病毒联合PD1/PD-L1治疗癌症/Oncolytic virus combined with PD1/PD-L1 to treat cancer
AAV在眼科疾病领域中的应用突破/Breakthrough in the application of AAV in the field of ophthalmic diseases
溶瘤病毒产品商业化生产的机遇和挑战/Opportunities and challenges for commercial production of oncolytic virus products
mRNA疫苗开发的进展和未来展望
第三届CDMO未来发展论坛主要话题:
抗体药物生产上游工艺开发及优化/Upstream process development and optimization of antibody drug production
抗体药物生产下游连续工艺:当下趋势与挑战/Progression of continuous downstream processing of monoclonal antibodies: current trends and challenges
CDMO角度分析细胞与基因治疗产业化面临的挑战和未来展望/CDMO analysis of the challenges and future prospects of the industrialization of cell and gene therapy
抗体药物商业化生产的关键要素/The key elements of the commercial production of antibody drugs
基因治疗药物的生产工艺开发策略和案例分享/Gene therapy drug production process development strategy and case sharing
圆桌讨论:中国CDMO未来发展之路/Panel Discussion:The future development of China’s CDMO
全球一次性工艺技术市场与展望/Global Single-use Bioprocessing Market Outlook and Forecast
一次性工艺技术在生物制药领域的应用机会与实践/Application opportunities and practices of disposable process technology in the field of biopharmaceuticals
生物制药:一次性生产工艺VS不锈钢生物反应器/Single-Use VS StainlessSteel Bioreactors for Biopharma
双抗CMC下游纯化及分析方法开发案例分享/Case sharing of double antibody CMC downstream purification and analysis method development
GmP生产中生产工艺变更和管理/Production process change and management in GmP production
药品全生命周期工艺开发和技术转移中的质量保证/Quality Assurance in Process Development and Technology Transfer of Drugs in Whole Life Cycle
全生命周期管理助力生物制药创新/Driving Innovation of BioPharma Products Through Life Cycle Planning
数字化技术助力生物药GMP生产/Pharma 4.0: Why digitize production
创新+国际化,打造全球领先的质量管理体系/Innovation + internationalization, to build a world-leading quality management system
基于QbD的细胞培养工艺开发
CDMO赋能中国生物制药发展/CDMO empowers China’s biopharmaceutical development
60个展位火热预订,演讲赞助,椅背赞助,横幅赞助等火热开选,3月18日前更有7折优惠等你抢!
往届会后报告,往届参会人员名单,展台,赞助方案等请联系工作人员
 
往届会议盛况

 
 
 

发表回复

您的电子邮箱地址不会被公开。 必填项已用*标注